Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes

This publication has 30 references indexed in Scilit:

• Discovery, biochemistry and biology of lovastatin
  The American Journal of Cardiology, 1988
• Lipid and lipoprotein metabolism in Hep G2 cells
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
• HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
  New England Journal of Medicine, 1988
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• The human LDL receptor: A cysteine-rich protein with multiple Alu sequences in its mRNA
  Cell, 1984
• Catabolism of human low density lipoproteins by human hepatoma cell line HepG2
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1984
• Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.
  Circulation, 1984
• Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1983
• Inhibitory Effects on Lipid Metabolismn in Cultured Cells of ML‐236B, a Potent Inhibitor of 3‐Hydroxt‐3‐methylglutaryl‐Cornzyme‐A Reductase
  European Journal of Biochemistry, 1978
• Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity
  FEBS Letters, 1976